Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 14, 23 | -1.05 Increased by +25.00% | -0.86 Decreased by -22.09% |
| May 8, 23 | -0.82 Increased by +54.44% | -0.86 Increased by +4.65% |
| Mar 30, 23 | -1.02 Increased by +43.33% | -1.34 Increased by +23.88% |
| Mar 20, 23 | -1.02 Increased by +36.25% | -1.34 Increased by +23.88% |
| Nov 1, 22 | -1.40 Increased by 0.00% | -1.65 Increased by +15.15% |
| Aug 15, 22 | -1.80 Decreased by -50.00% | -1.80 |
| May 5, 22 | -1.80 Decreased by -12.50% | -1.53 Decreased by -17.65% |
| Mar 28, 22 | -1.60 Increased by +33.33% | -1.60 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.79 M Increased by +77.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.55 M Increased by +46.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -4.39 M Increased by +35.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -6.25 M Increased by +6.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -7.94 M Decreased by -39.69% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -8.42 M Decreased by -20.76% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -6.80 M Decreased by -36.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -6.70 M Decreased by -33.47% | Decreased by N/A% Decreased by N/A% |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.